Navigation Links
Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
Date:8/30/2007

se a single blood specimen to identify chromosomal abnormalities associated with up to 85 developmental disorders. A positive result may be confirmed using a licensed fluorescence in situ hybridization (FISH) methodology. The company expects to provide test results from its ClariSure assay to physicians within five days of receiving a specimen at a Quest Diagnostics laboratory.

"While CGH microarrays often are used for research purposes, the considerable expertise and development required to commercialize these technologies has limited their use for diagnostic testing," said Joyce Schwartz, M.D., vice president and chief laboratory officer. "Our ClariSure assay bridges the gap between scientific research and real-world testing, affording physicians with a faster technique for diagnosing patients suspected of having a developmental disorder. With better diagnostic insights, parents can provide their child with appropriate schooling and social support, and understand the likelihood that other offspring may have the same disorder."

Quest Diagnostics owns the intellectual property underlying its microarray technology, which is used to analyze information contained within an individual's genetic makeup. CGH microarray technologies compare and contrast a specimen's DNA to the DNA of a healthy individual to identify, at a high resolution, extra or missing genetic material in the specimen. These technologies can detect a substantial proportion of additional abnormalities even in patients who have already had extensive cytogenetic and/or fluorescence in situ hybridization testing.(2) CGH microarray technologies are also more efficient, as multiple FISH tests are required to generate the same amount of information produced from one microarray-based test.

Quest Diagnostics' ClariSure test will be first introduced to physicians at pediatric and children's hospitals, with an emphasis on pediatricians, geneticists and pediatric neurologists.

Future ClariSu
'/>"/>

SOURCE Quest Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. To Stent or Not: Is That the Question?
4. Quest PharmaTechs Prostate Cancer Program Update
5. VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting
6. Afid Therapeutics Obtains Positive Evaluation of its Triple Mode Viral Sequestration Agents
7. New Advances in Gastric Diagnostics: Smaller is Better
8. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
9. Researchers Discover Method for Identifying How Cancer Evades the Immune System
10. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... and HOUSTON, TX , ... the "Company") (TSX-V: EPI) and Bloom Burton & Co. ... from voluntary contractual lock-up (the "Lock-Up") 2,353,130 common shares ... Common Shares originally subject to the Lock-Up. Of the ... be free trading immediately upon release from the Lock-Up ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... N.C., Dec. 21, 2010 Charlotte Business Journal ... an affiliate of Diagnostic Devices Inc. – one of ... an awards luncheon held at the Charlotte Convention Center ... recognizes Charlotte area companies for their leadership, entrepreneurial excellence, ...
... 21, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... Executive Officer, will host a conference call and webcast tomorrow, ... a.m. Pacific Time) to provide an update following the completion ... Administration (FDA) for the lorcaserin New Drug Application (NDA). ...
Cached Medicine Technology:Charlotte Business Journal Honors Prodigy Diabetes Care, LLC With Fast 50 Award 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 2Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA 3
(Date:2/28/2015)... 2015 Heart diseases are on the ... of urban adult population and 5 percent of rural ... and 20-30 percent of them require specialized investigation and ... coronary vascular diseases (CVD). , A division of Indian ... research report titled “Indian Coronary Stent Market Forecast to ...
(Date:2/28/2015)... With their commitment to achieving physical ... additional exercise to their already robust library of oblique ... commonly known as, is often performed on a stationary ... in a relatively safe manner and can be performed ... full description of “Rope Pulls” is located in the ...
(Date:2/28/2015)... 28, 2015 March—also known as ... to remind ourselves and others that suspected head ... NeuroSurgical Specialists (ANS). , Concussions are a form ... 75% of TBIs. There are 1.6-3.8 million sports-related ... benign, but it is a brain injury. Many ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4
... HealthDay Reporter , FRIDAY, Aug. 13 (HealthDay News) ... acetaminophen, best known as Tylenol, were more than twice ... take the over-the-counter pain and fever reducer, new research ... increased chance of eczema and rhinoconjunctivitis, or allergic nasal ...
... to adopt electronic medical records helps speed adoption by ... in the current issue of Management Science , ... and the Management Sciences (INFORMS)., "Social Contagion and Information ... U.S. Hospitals" is by Corey M. Angst and Ken ...
... Institute for Environmental Education and Research is helping ... local workers to create a pool of green ... and energy efficiency. A handful of local ... a U.S. Labor Department Energy Training Partnership grant, ...
... of Medicine today announced that the National Institutes of ... of Food Allergy Research (CoFAR), providing an additional $29.9 ... of food allergy. Mount Sinai is the primary research ... country. Under the renewed grant, Mount Sinai researchers ...
... Glioblastoma multiforme is the most common form of brain cancer; ... on diagnosis, the chances of survival of the patient is ... known nor the manner to prevent it. What is more, ... in 40 years, unlike other cancers such as, for example, ...
... LOS ANGELES (Aug. 11, 2010) Understanding the underlying genetic weakness ... and provide the key to effective treatment, a new study ... an investigational drug, Olaparib, can reduce the size of tumors ... mutations. The Phase II ovarian cancer ...
Cached Medicine News:Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 2Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 3Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 4Health News:Speed electronic medical record adoption via key medical centers, says Management Science 2Health News:Carnegie Mellon's Steinbrenner Institute helps grow green jobs 2Health News:Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant 2Health News:Multidisciplinary treatment of glioblastoma multiforme can extend patient's life 2Health News:New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer 2
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: